Ken Cook

Ken Cook

Auto-generated profile, based on publicly available information

Ken Cook

Thermo Fisher Scientific (United Kingdom)

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2022 in Analytical Chemistry
Verified
Journal Article
Open access
CVChristina J. Vanhinsbergh
Christina J. Vanhinsbergh
ACAngela Criscuolo
Angela Criscuolo
JSJennifer N. Sutton
Jennifer N. Sutton
KMKeeley Murphy
Keeley Murphy
AWAndrew J. K. Williamson
Andrew J. K. Williamson
MDMark J. Dickman
Mark J. Dickman
Large RNA including mRNA (mRNA) has emerged as an important new class of therapeutics. Recently, this has been demonstrated by two highly efficacious vaccines based on mRNA sequences encoding for a modified version of the SARS-CoV-2 spike protein. There is currently significant demand for the development of new and improved analytical methods for the characterization of large RNA including mRNA therapeutics. In this study, we have developed an automated, high-throughput workflow for the rapid characterization and direct sequence mapping of large RNA and mRNA therapeutics. Partial RNase digestions using RNase T1 immobilized on magnetic particles were performed in conjunction with high-resolution liquid chromatography-mass spectrometry analysis. Sequence mapping was performed using automated oligoribonucleotide annotation and identifications based on MS/MS spectra. Using this approach, a >80% sequence of coverage of a range of large RNAs and mRNA therapeutics including the SARS-CoV-2 spike protein was obtained in a single analysis. The analytical workflow, including automated sample preparation, can be completed within 90 min. The ability to rapidly identify, characterize, and sequence map large mRNA therapeutics with high sequence coverage provides important information for identity testing, sequence validation, and impurity analysis.

24 September 2020 in Analytical Chemistry
Verified
Journal Article
Closed access
JBJulia Baek
Julia Baek
ASAlexander B. Schwahn
Alexander B. Schwahn
SLShanhua Lin
Shanhua Lin
CPChristopher A. Pohl
Christopher A. Pohl
MPMauro De Pra
Mauro De Pra
KCKen Cook
Ken Cook

22 July 2021 in Analytical Chemistry
Verified
Journal Article
Closed access
ETEstee Naggar Toole
Estee Naggar Toole
CDCraig Dufresne
Craig Dufresne
SRSomak Ray
Somak Ray
ASAlexander Schwann
Alexander Schwann
KCKen Cook
Ken Cook
AIAlexander R. Ivanov
Alexander R. Ivanov

16 November 2022 in Analytical Chemistry
Verified
Journal Article
Open access
ASAlexander B. Schwahn
Alexander B. Schwahn
JBJulia Baek
Julia Baek
SLShanhua Lin
Shanhua Lin
CPChristopher A. Pohl
Christopher A. Pohl
KCKen Cook
Ken Cook
Characterization and quality control of biotherapeutic proteins commonly require the application of several orthogonal separation techniques in order to establish product identity and purity. Many of the techniques used rely on a buffered aqueous mobile phase system to maintain the native conformation of the protein and its variants. Optimal pH, buffer substance(s), and chromatography methods vary with each protein of interest and result in tedious method development for each new drug product. Linear controlled pH gradient systems from pH 5.6 to pH 10.2 has been shown to provide a global method for the separation of charge variants of monoclonal antibodies. This can be realized using two balanced zwitterionic buffer blends. The pH linearity of the resulting system, with a cation ion exchange column in place, can generate any pH value in this accessible pH range. This study expands the scope of this buffer system and demonstrates its application in conjunction with a quaternary HPLC pump for several analytical techniques: the pH optimization of salt gradient-based anion and cation exchange during method development, as well as performing pH gradient elution. In addition, the same universal buffers are used for hydrophobic interaction and size exclusion chromatography. This eluent system omits the need to prepare different buffers for each method and flushing of the HPLC system between method changes. The implementation of this concept is further demonstrated to allow an automated method scouting approach and selection of different methods that requires minimal manual intervention.

23 March 2026 in Analytical Chemistry
Verified
Journal Article
Open access
JDJessica S. Dale
Jessica S. Dale
EWEmma N. Welbourne
Emma N. Welbourne
CECaroline A. Evans
Caroline A. Evans
TMThomas C. Minshull
Thomas C. Minshull
ASAlexander B. Schwahn
Alexander B. Schwahn
MDMark J. Dickman
Mark J. Dickman
Mass spectrometry-based approaches have emerged as powerful tools for the analysis of a wide range of critical quality attributes of mRNA medicines, including sequence identity, 5' capping efficiency, and 3' poly(A) tail length and heterogeneity. These critical quality attributes can impact the quality, safety, and efficacy of mRNA medicines. In this study, we have utilized online partial RNase T1 digests in conjunction with two-dimensional liquid chromatography mass spectrometry (2D LC-MS) for the direct sequence mapping of mRNA. Automated online partial RNase T1 digests are performed in conjunction with ion-pair reversed-phase liquid chromatography. No sample or solvent manipulation is required following online RNase digestions, demonstrating the simplicity of the method. High-resolution tandem mass spectrometry was used to identify the corresponding oligoribonucleotides and generate mRNA sequence maps. High sequence coverage (93-99%) for eGFP mRNA was obtained in <60 min based only on unique oligoribonucleotide identifications. Moreover, the online partial RNase T1 digests result in controlled, fully automated and reproducible mRNA digests, enabling high-throughput, direct mRNA sequence mapping studies. The online partial RNase digests offer significant advantages over existing methods for rapid, automated mRNA identity testing. Furthermore, precise control of the digest conditions via flow rate and temperature of the online RNase T1 digest, enables multiattribute monitoring of 5' capping efficiency, mRNA sequence mapping, and 3' poly(A) tail length and heterogeneity in a fully automated 2D LC-MS workflow.

12 August 2025 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Open access
SMSilvia Millán-Martín
Silvia Millán-Martín
FGFelipe Guapo
Felipe Guapo
SCSara Carillo
Sara Carillo
UMUlrik H. Mistarz
Ulrik H. Mistarz
KCKen Cook
Ken Cook
JBJonathan Bones
Jonathan Bones
Oligonucleotides offer a powerful class of new therapeutic modalities, which requires the support of robust and sensitive analytical methods. The primary structure of RNA-based therapeutic drugs is considered a critical quality attribute by regulatory agencies, and must be empirically confirmed to ensure quality, safety and efficacy, together with the analysis of the 5' and 3' termini, and any site-specific modifications. This study highlights the use of amine-based ion pair reversed-phase LC coupled to a high-resolution MS and MS/MS method (HRMS) for the characterisation of small RNA-based molecules, single stranded antisense oligonucleotides (ss-ASOs), designed with different chemical modifications from second and third generation categories, including backbone modifications, sugar modifications at the 2' position and base modifications. The study evaluates the applicability of an alternative ion pairing reagent, with moderate hydrophobicity, and the use of a mild ESI source, with the aim to reduce the formation of ion pair-adducts and in-source induced impurities. The developed method allows for sequence verification and confident identification of low abundant impurities with high sensitivity and high mass accuracy at the intact and sequencing level. Intact analysis allowed for the detection and quantification of full-length products with different sizes and purity values, and the detection of multiple impurities and degradants, even without being fully chromatographically resolved, with high sensitivity. Most common impurity found in analysed RNA-based ss-ASOs was the presence of the phosphodiester (PO) conversion, with fractional abundances from 9.2 % to 1.2 %, followed by failure sequence shortmers.